Clinical trials

At GenesisCare, we challenge ourselves every day to find new and better ways to treat illness and disease and deliver better outcomes for our patients.

Search for clinical trials by location and speciality

To evaluate the safety and effectiveness of a new ablation catheter used in patients to treat drug refractory, symptomatic, paroxysmal atrial fibrillation.

Location: Brisbane


To confirm the safety and efficacy of an implantable cardiac monitor (ICM) in patients who require long term cardiac monitoring due to suspected cardiac arrhythmia or unexplained syncope.

Location: Brisbane, Bundaberg, Melbourne


To assess the clinical safety and feasibility of MultiPulse Therapy (low voltage and energy used to terminate tachyarrhythmias) in subjects with paroxysmal and persistent Atrial Fibrillation (AF) during their clinically indicated atrial fibrillation catheter ablation procedure.

Location: Melbourne, Adelaide


22 June, 2020

Heart Failure - VFAHF

To collect data and evaluate the safety of Cardiac Resynchronisation Therapy (CRT) by utilising new techniques and investigational systems for patients in heart failure.

Location: Melbourne


To evaluate the efficacy and safety of a new device using Cardiac Contractility Modulation (CCM) therapy in patients with heart failure.

Location: Perth, Adelaide, Bundaberg


A significant number of patients with heart failure implanted with a Cardiac Resynchronisation Therapy (CRT) device fail to respond to therapy. The cause of this non-response is yet to be determined.    The purpose of this study is to assess the pattern of electrical wiring of the heart, identify the variations seen in individuals with heart failure and their response to CRT. This study will also evaluate the link of CRT response to septal scar (heart scar tissue) and patterns of electrocardiogram (ECG). 

Location: Adelaide, Brisbane, Perth, Melbourne


30 October, 2019

Aortic Valve Stenosis

PORTICO-NG

To evaluate a new valve, the Portico™ NG Transcatheter Aortic Heart Valve, in patients who have symptomatic, severe aortic stenosis and are determined to be at high or extreme surgical risk 

Location: Adelaide, Brisbane


30 October, 2019

Atrial Fibrillation

OPTION

To evaluate a new implantable device, the Watchman FLX in patients with non-valvular atrial fibrillation who have an increased stroke risk.

29 October, 2019

Cardiovascular Disease

VESALIUS

To evaluate if treatment with additional cholesterol lowering medication reduces the risk of major cardiovascular events in patients at high cardiovascular risk

Location: Adelaide, Brisbane, Perth, Bundaberg, Melbourne


22 August, 2019

Cardio-Oncology

SUCCOUR MRI SUB-STUDY

To evaluate if treatment with two cardioprotective medications reduces the risk of developing heart failure in participants currently undergoing chemotherapy

Location: Melbourne, Mulgrave, Brisbane, Perth


22 August, 2019

Heart Failure

HEART-FID

To evaluate a new medication for the treatment of patients in heart failure with a reduced ejection fraction and with iron deficiency.

Location: Brisbane


To evaluate a new valve in patients with severe mitral regurgitation

Location: Adelaide, Brisbane, Melbourne, Perth


15 May, 2019

Heart Failure Device

COAST

To evaluate a new heart failure sensing device in patients with heart failure

Location: Brisbane


24 April, 2019

Cardiovascular disease and obesity

SELECT

To evaluate if treatment with a new medication reduces the risk of cardiovascular disease in overweight or obese patients

Location: Brisbane, Perth

Clinical Trials

At GenesisCare, we challenge ourselves every day to find new and better ways to treat illness and disease and deliver better outcomes for our patients.

Atrial Fibrillation - TactiFlex PAF IDE

To evaluate the safety and effectiveness of a new ablation catheter used in patients to treat drug refractory, symptomatic, paroxysmal atrial fibrillation.

Wesley Hospital Auchenflower (Cardiology)

Level 5, Suite 91 Sandford Jackson Building 30 Chasely Street Auchenflower QLD 4066

Syncope/Cardiac arrhythmia for investigation - BIOMASTER

To confirm the safety and efficacy of an implantable cardiac monitor (ICM) in patients who require long term cardiac monitoring due to suspected cardiac arrhythmia or unexplained syncope.

Wesley Hospital Auchenflower (Cardiology)

Level 5, Suite 91 Sandford Jackson Building 30 Chasely Street Auchenflower QLD 4066

Syncope/Cardiac arrhythmia for investigation - BIOMASTER

To confirm the safety and efficacy of an implantable cardiac monitor (ICM) in patients who require long term cardiac monitoring due to suspected cardiac arrhythmia or unexplained syncope.

Friendly Society Private Hospital Bundaberg (Cardiology)

Floor 1, 19-23 Bingera Street, Bundaberg QLD 4670

Syncope/Cardiac arrhythmia for investigation - BIOMASTER

To confirm the safety and efficacy of an implantable cardiac monitor (ICM) in patients who require long term cardiac monitoring due to suspected cardiac arrhythmia or unexplained syncope.

Doncaster East (Cardiology)

Suite 1, 1008 Doncaster Road, Doncaster East VIC 3109

Atrial Fibrillation - Cardialen AF CL007

To assess the clinical safety and feasibility of MultiPulse Therapy (low voltage and energy used to terminate tachyarrhythmias) in subjects with paroxysmal and persistent Atrial Fibrillation (AF) during their clinically indicated atrial fibrillation catheter ablation procedure.

Doncaster East (Cardiology)

Suite 1, 1008 Doncaster Road, Doncaster East VIC 3109

Atrial Fibrillation - Cardialen AF CL007

To assess the clinical safety and feasibility of MultiPulse Therapy (low voltage and energy used to terminate tachyarrhythmias) in subjects with paroxysmal and persistent Atrial Fibrillation (AF) during their clinically indicated atrial fibrillation catheter ablation procedure.

Berwick (Cardiology)

Unit 2, 11 Gloucester Avenue, Berwick VIC 3806

Atrial Fibrillation - Cardialen AF CL007

To assess the clinical safety and feasibility of MultiPulse Therapy (low voltage and energy used to terminate tachyarrhythmias) in subjects with paroxysmal and persistent Atrial Fibrillation (AF) during their clinically indicated atrial fibrillation catheter ablation procedure.

Leabrook (Cardiology)

284 Kensington Road, Leabrook, SA 5068

Atrial Fibrillation - Cardialen AF CL007

To assess the clinical safety and feasibility of MultiPulse Therapy (low voltage and energy used to terminate tachyarrhythmias) in subjects with paroxysmal and persistent Atrial Fibrillation (AF) during their clinically indicated atrial fibrillation catheter ablation procedure.

Greenslopes (Cardiology)

Ramsay Specialist Centre Suite 212, Level 2 Newdegate Street, Greenslopes, QLD, 4120

Heart Failure - VFAHF

To collect data and evaluate the safety of Cardiac Resynchronisation Therapy (CRT) by utilising new techniques and investigational systems for patients in heart failure.

Doncaster East (Cardiology)

Suite 1, 1008 Doncaster Road, Doncaster East VIC 3109

Heart Failure - OPTIMIZER CCM

To evaluate the efficacy and safety of a new device using Cardiac Contractility Modulation (CCM) therapy in patients with heart failure.

Murdoch (Cardiology)

St John of God Wexford Medical Centre, Level 4, Suite 68-72, 3 Barry Marshall Parade, Murdoch, WA 6150

Heart Failure - OPTIMIZER CCM

To evaluate the efficacy and safety of a new device using Cardiac Contractility Modulation (CCM) therapy in patients with heart failure.

Leabrook (Cardiology)

284 Kensington Road, Leabrook, SA 5068

Heart Failure - OPTIMIZER CCM

To evaluate the efficacy and safety of a new device using Cardiac Contractility Modulation (CCM) therapy in patients with heart failure.

Friendly Society Private Hospital Bundaberg (Cardiology)

Floor 1, 19-23 Bingera Street, Bundaberg QLD 4670

Heart Failure - OPTIMIZER CCM

To evaluate the efficacy and safety of a new device using Cardiac Contractility Modulation (CCM) therapy in patients with heart failure.

Bunbury (Cardiology)

Suite 21, St John of God Hospital, Southwest Health Campus, Corner of Roberston Drive & Bussell Highway, WA, 6230

Heart Failure and Cardiac Resynchronisation Therapy

SMART

A significant number of patients with heart failure implanted with a Cardiac Resynchronisation Therapy (CRT) device fail to respond to therapy. The cause of this non-response is yet to be determined.    The purpose of this study is to assess the pattern of electrical wiring of the heart, identify the variations seen in individuals with heart failure and their response to CRT. This study will also evaluate the link of CRT response to septal scar (heart scar tissue) and patterns of electrocardiogram (ECG). 

Leabrook (Cardiology)

284 Kensington Road, Leabrook, SA 5068

Heart Failure and Cardiac Resynchronisation Therapy

SMART

A significant number of patients with heart failure implanted with a Cardiac Resynchronisation Therapy (CRT) device fail to respond to therapy. The cause of this non-response is yet to be determined.    The purpose of this study is to assess the pattern of electrical wiring of the heart, identify the variations seen in individuals with heart failure and their response to CRT. This study will also evaluate the link of CRT response to septal scar (heart scar tissue) and patterns of electrocardiogram (ECG). 

Wesley Hospital Auchenflower (Cardiology)

Level 5, Suite 91 Sandford Jackson Building 30 Chasely Street Auchenflower QLD 4066

Heart Failure and Cardiac Resynchronisation Therapy

SMART

A significant number of patients with heart failure implanted with a Cardiac Resynchronisation Therapy (CRT) device fail to respond to therapy. The cause of this non-response is yet to be determined.    The purpose of this study is to assess the pattern of electrical wiring of the heart, identify the variations seen in individuals with heart failure and their response to CRT. This study will also evaluate the link of CRT response to septal scar (heart scar tissue) and patterns of electrocardiogram (ECG). 

Murdoch (Cardiology)

St John of God Wexford Medical Centre, Level 4, Suite 68-72, 3 Barry Marshall Parade, Murdoch, WA 6150

Heart Failure and Cardiac Resynchronisation Therapy

SMART

A significant number of patients with heart failure implanted with a Cardiac Resynchronisation Therapy (CRT) device fail to respond to therapy. The cause of this non-response is yet to be determined.    The purpose of this study is to assess the pattern of electrical wiring of the heart, identify the variations seen in individuals with heart failure and their response to CRT. This study will also evaluate the link of CRT response to septal scar (heart scar tissue) and patterns of electrocardiogram (ECG). 

Bundoora (Cardiology)

Health and Wellness Centre Level 1, Suites 8-10, 20 Scholar Drive, Bundoora VIC 3083

Aortic Valve Stenosis

PORTICO-NG

To evaluate a new valve, the Portico™ NG Transcatheter Aortic Heart Valve, in patients who have symptomatic, severe aortic stenosis and are determined to be at high or extreme surgical risk 

Leabrook (Cardiology)

284 Kensington Road, Leabrook, SA 5068

Aortic Valve Stenosis

PORTICO-NG

To evaluate a new valve, the Portico™ NG Transcatheter Aortic Heart Valve, in patients who have symptomatic, severe aortic stenosis and are determined to be at high or extreme surgical risk 

Wesley Hospital Auchenflower (Cardiology)

Level 5, Suite 91 Sandford Jackson Building 30 Chasely Street Auchenflower QLD 4066

Aortic Valve Stenosis

PORTICO-NG

To evaluate a new valve, the Portico™ NG Transcatheter Aortic Heart Valve, in patients who have symptomatic, severe aortic stenosis and are determined to be at high or extreme surgical risk 

Mater Brisbane (Cardiology)

Mater Private Clinic Suite 5.02 & 5.11, Level 5 550 Stanley Street South Brisbane QLD 4101

Atrial Fibrillation

OPTION

To evaluate a new implantable device, the Watchman FLX in patients with non-valvular atrial fibrillation who have an increased stroke risk.

Greenslopes (Cardiology)

Ramsay Specialist Centre Suite 212, Level 2 Newdegate Street, Greenslopes, QLD, 4120

Cardiovascular Disease

VESALIUS

To evaluate if treatment with additional cholesterol lowering medication reduces the risk of major cardiovascular events in patients at high cardiovascular risk

Leabrook (Cardiology)

284 Kensington Road, Leabrook, SA 5068

Cardiovascular Disease

VESALIUS

To evaluate if treatment with additional cholesterol lowering medication reduces the risk of major cardiovascular events in patients at high cardiovascular risk

Wesley Hospital Auchenflower (Cardiology)

Level 5, Suite 91 Sandford Jackson Building 30 Chasely Street Auchenflower QLD 4066

Cardiovascular Disease

VESALIUS

To evaluate if treatment with additional cholesterol lowering medication reduces the risk of major cardiovascular events in patients at high cardiovascular risk

Joondalup – Shenton House (Cardiology)

Level 3, Shenton House, 57 Shenton Avenue, Joondalup, WA 6027

Cardiovascular Disease

VESALIUS

To evaluate if treatment with additional cholesterol lowering medication reduces the risk of major cardiovascular events in patients at high cardiovascular risk

Friendly Society Private Hospital Bundaberg (Cardiology)

Floor 1, 19-23 Bingera Street, Bundaberg QLD 4670

Cardiovascular Disease

VESALIUS

To evaluate if treatment with additional cholesterol lowering medication reduces the risk of major cardiovascular events in patients at high cardiovascular risk

Berwick (Cardiology)

Unit 2, 11 Gloucester Avenue, Berwick VIC 3806

Cardiovascular Disease

VESALIUS

To evaluate if treatment with additional cholesterol lowering medication reduces the risk of major cardiovascular events in patients at high cardiovascular risk

Ringwood (Cardiology)

Level 2, Suite 22 & 23, 50 New Street, Ringwood VIC 3134

Cardio-Oncology

SUCCOUR MRI SUB-STUDY

To evaluate if treatment with two cardioprotective medications reduces the risk of developing heart failure in participants currently undergoing chemotherapy

Heidelberg (Cardiology)

Warringal Private Hospital, Suite 1, 216 Burgundy Street, Heidelberg VIC 3084

Cardio-Oncology

SUCCOUR MRI SUB-STUDY

To evaluate if treatment with two cardioprotective medications reduces the risk of developing heart failure in participants currently undergoing chemotherapy

Bundoora (Cardiology)

Health and Wellness Centre Level 1, Suites 8-10, 20 Scholar Drive, Bundoora VIC 3083

Cardio-Oncology

SUCCOUR MRI SUB-STUDY

To evaluate if treatment with two cardioprotective medications reduces the risk of developing heart failure in participants currently undergoing chemotherapy

Mulgrave (Cardiology)

Mulgrave Private Hospital, Churchill Consulting Suites, Blanton Drive, Mulgrave VIC 3170

Cardio-Oncology

SUCCOUR MRI SUB-STUDY

To evaluate if treatment with two cardioprotective medications reduces the risk of developing heart failure in participants currently undergoing chemotherapy

Berwick (Cardiology)

Unit 2, 11 Gloucester Avenue, Berwick VIC 3806

Cardio-Oncology

SUCCOUR MRI SUB-STUDY

To evaluate if treatment with two cardioprotective medications reduces the risk of developing heart failure in participants currently undergoing chemotherapy

Wesley Hospital Auchenflower (Cardiology)

Level 5, Suite 91 Sandford Jackson Building 30 Chasely Street Auchenflower QLD 4066

Cardio-Oncology

SUCCOUR MRI SUB-STUDY

To evaluate if treatment with two cardioprotective medications reduces the risk of developing heart failure in participants currently undergoing chemotherapy

Murdoch (Cardiology)

St John of God Wexford Medical Centre, Level 4, Suite 68-72, 3 Barry Marshall Parade, Murdoch, WA 6150

Cardio-Oncology

SUCCOUR MRI SUB-STUDY

To evaluate if treatment with two cardioprotective medications reduces the risk of developing heart failure in participants currently undergoing chemotherapy

Doncaster East (Cardiology)

Suite 1, 1008 Doncaster Road, Doncaster East VIC 3109

Cardio-Oncology

SUCCOUR MRI SUB-STUDY

To evaluate if treatment with two cardioprotective medications reduces the risk of developing heart failure in participants currently undergoing chemotherapy

Ringwood (Cardiology)

Level 2, Suite 22 & 23, 50 New Street, Ringwood VIC 3134

Heart Failure

HEART-FID

To evaluate a new medication for the treatment of patients in heart failure with a reduced ejection fraction and with iron deficiency.

Wesley Hospital Auchenflower (Cardiology)

Level 5, Suite 91 Sandford Jackson Building 30 Chasely Street Auchenflower QLD 4066

Heart Failure due to mitral valve regurgitation

HighLife

To evaluate a new valve in patients with severe mitral regurgitation

Leabrook (Cardiology)

284 Kensington Road, Leabrook, SA 5068

Heart Failure due to mitral valve regurgitation

HighLife

To evaluate a new valve in patients with severe mitral regurgitation

Wesley Hospital Auchenflower (Cardiology)

Level 5, Suite 91 Sandford Jackson Building 30 Chasely Street Auchenflower QLD 4066

Heart Failure due to mitral valve regurgitation

HighLife

To evaluate a new valve in patients with severe mitral regurgitation

Doncaster East (Cardiology)

Suite 1, 1008 Doncaster Road, Doncaster East VIC 3109

Heart Failure due to mitral valve regurgitation

HighLife

To evaluate a new valve in patients with severe mitral regurgitation

Murdoch (Cardiology)

St John of God Wexford Medical Centre, Level 4, Suite 68-72, 3 Barry Marshall Parade, Murdoch, WA 6150

Heart Failure Device

COAST

To evaluate a new heart failure sensing device in patients with heart failure

Wesley Hospital Auchenflower (Cardiology)

Level 5, Suite 91 Sandford Jackson Building 30 Chasely Street Auchenflower QLD 4066

Cardiovascular disease and obesity

SELECT

To evaluate if treatment with a new medication reduces the risk of cardiovascular disease in overweight or obese patients

Wesley Hospital Auchenflower (Cardiology)

Level 5, Suite 91 Sandford Jackson Building 30 Chasely Street Auchenflower QLD 4066

Cardiovascular disease and obesity

SELECT

To evaluate if treatment with a new medication reduces the risk of cardiovascular disease in overweight or obese patients

Joondalup – Shenton House (Cardiology)

Level 3, Shenton House, 57 Shenton Avenue, Joondalup, WA 6027